Stoxline.com
android_stock_chart
Stock Chart

Stoxline Lite

Stoxline Pro

Option Calculator
Stoxline
Mobile

Home | Charts | Showcases | Stock Ranks | Options | ETFs | Educations

 
Tweet this page
Share on Facebook
Share on Google+

7 Binary Options

 

Enter Stock Symbol:  

Akari Therapeutics- Plc (AKTX)

2.09 -0.03 (-1.42%)

07-18 16:00

Open:

2.1029

Pre. Close:

2.12

High:

2.12

Low:

1.96

Volume:

58,001

Market Cap:

32M

Stock Price Prediction (Update at 5:00pm est.)

If tomorrow:

Open lower

Open higher

High:

2.122 - 2.134

2.134 - 2.143

Low:

1.933 - 1.947

1.947 - 1.958

Close:

2.068 - 2.09

2.09 - 2.109

Technical analysis  (as of: 2018-07-18 4:27:16 PM)

Overall:

      

Stoxline posted a SELL today, downgraded from higher rating. This stock seems to be ready for a new bearish move. So you may continue to hold short positions or sell your long positions. You are relatively safe to short or sell now, downward move is expected.

Target:

Six months: 2.60     One year: 2.87

Support:

Support1: 1.85    Support2: 1.54

Resistance:

Resistance1: 2.23    Resistance2: 2.46

Pivot:

2.06

Moving Averages:

MA(5): 2.11     MA(20): 2.06

MA(100): 2.00     MA(250): 3.41

MACD:

MACD(12,26): 0.03     Signal(12,26,9): 0.03

%K %D:

%K(14,3): 42.42     %D(3): 37.73

RSI:

RSI(14): 53.93

52-Week:

High: 11.95  Low: 1.701  Change(%): -55.4

Average Vol(K):

3-Month: 8236  10-Days 3587

Strong Sell ★★ Sell ★★★ Neutral ★★★★ Buy ★★★★★ Strong Buy

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
AKTX has closed below upper band by 33.3%. Bollinger Bands are 52.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to AKTX's normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

2018-05-31T09:04:00-04:00
Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 2)

2018-04-09T13:39:22-04:00
Achillion, Omeros, Ra Rx, Reata, Chemocentryx And Others In The IgA Nephropathy Space

2018-03-21T14:56:03-04:00
Akari Therapeutics' (AKTX) CEO David Solomon on Q4 2017 Results - Earnings Call Transcript

2018-03-21T08:45:58-04:00
Akari Therapeutics reports Q4 results

2018-03-15T07:30:55-04:00
Alexion's long-acting PNH candidate ALXN1210 on par with Soliris in late-stage study; shares up 11% premarket

2018-02-20T12:23:05-05:00
Alexion Ups Its Game With ALXN1210 SC

2018-02-06T09:17:54-05:00
Premarket Gainers as of 9:05 am (02/06/2018)

2018-02-06T08:02:54-05:00
Akari completes mid-stage study of Coversin in PNH; shares up 13% premarket

Financial Analysis

Growth

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.

Profitability

Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.

Solvency

Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.

Efficiency

NA

Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.

Click here to get more fundamental analysis.

 

Free Technical Analysis Charts

Stock Basics & Statistics

Sector:  Healthcare

Industry:  Bio Therapeutic Drugs

Shares Out. (M)

15.26

Shares Float (M)

13.94

% Held by Insiders

8.60

% Held by Institutions

10.20

Shares Short (K)

312

Shares Short Prior Month (K)

Stock Financials

EPS

-0.220

EPS Est. Current Year

-2.360

EPS Est. Next Year

-3.110

EPS Est. Next Quarter

-0.660

Forward EPS

-1.938

Book Value (p.s.)

2.430

PEG Ratio

Profit Margin

Operating Margin

Return on Assets (ttm)

-86.9

Return on Equity (ttm)

-120.5

Qtrly Rev. Growth

Gross Profit (p.s.)

Sales Per Share

EBITDA (p.s.)

-1.040

Qtrly Earnings Growth

Operating Cash Flow (M)

Levered Free Cash Flow (M)

atoplab.com

Valuation

P/E

-9.50

P/E Growth Ratio

-0.01

P/BV

0.86

P/S

P/CF

Dividend Yield

Dividends & Splits

Dividend

Dividend Pay Date

Invalid DateTime.

Ex-Dividend Date

Invalid DateTime.

Forward Dividend

Last Split Date

2015-09-17

Last Split Ratio

-1e+010

 

(c) 2006-2017 Stoxline.com | Contact us | NYSE, NASDAQ, AMEX Stock symbols

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.